{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T02:58:03Z","timestamp":1769914683953,"version":"3.49.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2020J011094"],"award-info":[{"award-number":["2020J011094"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s11096-022-01474-9","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T12:11:56Z","timestamp":1663848716000},"page":"1325-1331","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical validation of the two-point method for predicting vancomycin AUC based on peak and trough plasma concentrations"],"prefix":"10.1007","volume":"44","author":[{"given":"Liming","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6462-2357","authenticated-orcid":false,"given":"Junshan","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songqing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,22]]},"reference":[{"issue":"3","key":"1474_CR1","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/pro.3819","volume":"29","author":"PJ Stogios","year":"2020","unstructured":"Stogios PJ, Savchenko A. Molecular mechanisms of vancomycin resistance. Protein Sci. 2020;29(3):654\u201369.","journal-title":"Protein Sci"},{"issue":"4","key":"1474_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106109","volume":"56","author":"K Oda","year":"2020","unstructured":"Oda K, Jono H, Nosaka K, et al. Reduced nephrotoxicity with vancomycin therapeutic drug monitoring guided by area under the concentration-time curve against a trough 15\u201320 \u03bcg\/mL concentration. Int J Antimicrob Agents. 2020;56(4): 106109.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"1474_CR3","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ijantimicag.2018.12.014","volume":"53","author":"PG Drennan","year":"2019","unstructured":"Drennan PG, Begg EJ, Gardiner SJ, et al. The dosing and monitoring of vancomycin: what is the best way forward? Int J Antimicrob Agents. 2019;53(4):401\u20137.","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"1474_CR4","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3855\/jidc.9800","volume":"12","author":"WK Kabbara","year":"2018","unstructured":"Kabbara WK, El-Khoury G, Chamas NR. Prospective evaluation of vancomycin therapeutic usage and trough levels monitoring. J Infect Dev Ctries. 2018;12(11):978\u201384.","journal-title":"J Infect Dev Ctries"},{"issue":"11","key":"1474_CR5","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1093\/cid\/ciz051","volume":"69","author":"DM Aljefri","year":"2019","unstructured":"Aljefri DM, Avedissian SN, Rhodes NJ, et al. Vancomycin area under the curve and acute kidney injury: a meta-analysis. Clin Infect Dis. 2019;69(11):1881\u20137.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1474_CR6","first-page":"172","volume":"69","author":"H Such\u00e1nkov\u00e1","year":"2020","unstructured":"Such\u00e1nkov\u00e1 H, Le\u010dbychov\u00e1 K, Strojil J, et al. Individualized dosing of vancomycin in geriatric patients. Epidemiol Mikrobiol Imunol. 2020;69(4):172\u201380.","journal-title":"Epidemiol Mikrobiol Imunol"},{"issue":"12","key":"1474_CR7","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s40266-016-0420-z","volume":"33","author":"KE Barber","year":"2016","unstructured":"Barber KE, Bell AM, Stover KR, et al. Intravenous vancomycin dosing in the elderly: a focus on clinical issues and practical application. Drugs Aging. 2016;33(12):845\u201354.","journal-title":"Drugs Aging"},{"issue":"12","key":"1474_CR8","doi-asserted-by":"publisher","first-page":"e01293","DOI":"10.1128\/AAC.01293-17","volume":"61","author":"NA Finch","year":"2017","unstructured":"Finch NA, Zasowski EJ, Murray KP, et al. A quasi-experiment to study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity. Antimicrob Agents Chemother. 2017;61(12):e01293-e1317.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"1474_CR9","doi-asserted-by":"publisher","first-page":"1346.e1","DOI":"10.1016\/j.cmi.2020.11.008","volume":"27","author":"BV Lee","year":"2021","unstructured":"Lee BV, Fong G, Bolaris M, et al. Cost-benefit analysis comparing trough, two-level AUC and Bayesian AUC dosing for vancomycin. Clin Microbiol Infect. 2021;27(9):1346.e1-1346.e7.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"1474_CR10","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/phar.2234","volume":"39","author":"L Meng","year":"2019","unstructured":"Meng L, Wong T, Huang S, et al. Conversion from vancomycin trough concentration-guided dosing to area under the curve-guided dosing using two sample measurements in adults: implementation at an Academic Medical Center. Pharmacotherapy. 2019;39(4):433\u201342.","journal-title":"Pharmacotherapy"},{"issue":"5","key":"1474_CR11","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1128\/AAC.03147-14","volume":"60","author":"R \u00c1lvarez","year":"2016","unstructured":"\u00c1lvarez R, L\u00f3pez Cort\u00e9s LE, Molina J, et al. Optimizing the clinical use of vancomycin. Antimicrob Agents Chemother. 2016;60(5):2601\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1474_CR12","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ijantimicag.2018.12.014","volume":"53","author":"PG Drennan","year":"2019","unstructured":"Drennan PG, Begg EJ, Gardiner SJ, et al. The dosing and monitoring of vancomycin: what is the best way forward? Int J Antimicrob Agents. 2019;53(4):401\u20137.","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"1474_CR13","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s13318-019-00551-1","volume":"44","author":"FK Al-Sulaiti","year":"2019","unstructured":"Al-Sulaiti FK, Nader AM, Saad MO, et al. Clinical and pharmacokinetic outcomes of peak-trough-based versus trough-based vancomycin therapeutic drug monitoring approaches: a pragmatic randomized controlled trial. Eur J Drug Metab Pharmacokinet. 2019;44(5):639\u201352.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"4","key":"1474_CR14","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jhin.2012.12.011","volume":"83","author":"DN Shah","year":"2013","unstructured":"Shah DN, Bhatt NS, Welch JK, et al. Defining acute renal dysfunction as a criterion for the severity of Clostridium difficile infection in patients with community-onset vs hospital-onset infection. J Hosp Infect. 2013;83(4):294\u20139.","journal-title":"J Hosp Infect"},{"issue":"5","key":"1474_CR15","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1089\/mdr.2017.0147","volume":"24","author":"MO Ahmed","year":"2018","unstructured":"Ahmed MO, Baptiste KE. Vancomycin-resistant enterococci: a review of antimicrobial resistance mechanisms and perspectives of human and animal health. Microb Drug Resist. 2018;24(5):590\u2013606.","journal-title":"Microb Drug Resist"},{"issue":"9","key":"1474_CR16","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1093\/cid\/ciaa1744","volume":"72","author":"TP Lodise","year":"2021","unstructured":"Lodise TP, Drusano G. Vancomycin area under the curve-guided dosing and monitoring for adult and pediatric patients with suspected or documented serious methicillin-resistant Staphylococcus Aureus infections: putting the safety of our patients first. Clin Infect Dis. 2021;72(9):1497\u2013501.","journal-title":"Clin Infect Dis"},{"issue":"14","key":"1474_CR17","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1093\/ajhp\/zxaa128","volume":"77","author":"JA Cusumano","year":"2020","unstructured":"Cusumano JA, Klinker KP, Huttner A, et al. Towards precision medicine: Therapeutic drug monitoring-guided dosing of vancomycin and \u03b2-lactam antibiotics to maximize effectiveness and minimize toxicity. Am J Health Syst Pharm. 2020;77(14):1104\u201312.","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"1474_CR18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2146\/ajhp080434","volume":"66","author":"M Rybak","year":"2009","unstructured":"Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66(1):82\u201398.","journal-title":"Am J Health Syst Pharm"},{"issue":"6","key":"1474_CR19","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1093\/cid\/ciaa303","volume":"71","author":"MJ Rybak","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of Vancomycin for serious methicillin-resistant Staphylococcus Aureus infections: a revised consensus guideline and review by the American society of health-system pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2020;71(6):1361\u20134.","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-022-01474-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-022-01474-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-022-01474-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,4]],"date-time":"2022-12-04T20:02:55Z","timestamp":1670184175000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-022-01474-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,22]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1474"],"URL":"https:\/\/doi.org\/10.1007\/s11096-022-01474-9","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,22]]},"assertion":[{"value":"5 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}